期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝伐单抗在卵巢上皮性癌化疗中的应用进展 被引量：1

原文传递
导出
摘要 卵巢上皮性癌（卵巢癌）是常见的妇科恶性肿瘤，居女性恶性肿瘤死亡原因的第4位。近30年来，随着化疗方案的改进，卵巢癌的5年生存率从过去的37％提高到目前的45％，但仍有75％的卵巢癌患者诊断时已属晚期（Ⅲ～Ⅳ期），经肿瘤细胞减灭术＋标准一线化疗[即紫杉醇＋卡铂（TC）方案]后，多数患者可获临床完全缓解，但仍有50％以上的患者复发，终因肿瘤耐药而死亡。为改善卵巢癌患者的预后，世界范围内各大肿瘤中心正致力于研究卵巢癌的不同治疗策略（如巩固治疗、腹腔化疗等）和开发新的细胞毒化疗药物及针对特异性分子靶点的生物制剂，
作者 李淑敏 章文华
机构地区 中国医学科学院肿瘤医院妇瘤科
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2009年第6期475-477,共3页 Chinese Journal of Obstetrics and Gynecology
关键词 卵巢上皮性癌 化疗方案 贝伐单抗 卵巢癌患者 妇科恶性肿瘤 肿瘤细胞减灭术 女性恶性肿瘤 死亡原因
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献20

  • 1Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Onco1,2006,33 : S3-11.
  • 2Rosa DD, Clamp AR, Collinson F, et al. Antiangiogenic therapy for ovarian cancer. Curr Opin Oncol,2007,19:497-505.
  • 3Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol, 1998,153 : 1249-1256.
  • 4Aghajanian C. The role of bevacizumab in ovarian cancer: an evolving story. Gyneeol Oncol,2006,102 : 131-133.
  • 5Garzetti GG, Ciavattini A, Lucarini G, et al. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immuuostaining. Gynecol Oncol, 1999,73:396-401.
  • 6Tuma RS. Success of bevacizumab trials raises questions for future studies. J Natl Cancer Inst,2005 ,97 :950-951.
  • 7Monk B J, Choi DC, Pugmire G,et al. Activity of bevacizumab (rhuMAB VEGF ) in advanced refractory epithelial ovarian cancer. Gynecol Oncol,2005,96:902-905.
  • 8Kaye SB. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol,2007,25:5150- 5152.
  • 9Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol,2007,25:5165-5171.
  • 10Cannistra SA, Matulonis UA, Penson RT, et al. Phase Ⅱ study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol,2007,25:5180-5186.

二级参考文献9

  • 1Freidlin B, Korn EL, Hunsberger S, et al. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol, 2007, 25:2122-2126.
  • 2Hudis CA, Barlow WE, Costantino JP. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol, 2007, 25:2127-2132.
  • 3Jaffe CC. Measures of response: RECIST,WHO, and new alternatives. J Clin Oncol, 2006, 24:3245-3251.
  • 4Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol, 2007,25: 1760- 1764.
  • 5Kelloff GJ, Sigman CC. New science-based endpoints to accelerate ontology drug development. Eur J Cancer, 2005,41:491-501.
  • 6Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol, 2007, 25:1753-1759.
  • 7Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 2000, 92:205-216.
  • 8Flaherty KT. Sorafenib in renal cell carcinoma. Clin Cancer Res 2007, 132(Suppl) :747s-752s.
  • 9Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE- MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther, 2008, 7 : 1-6.

共引文献6

同被引文献12

  • 1Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011 :the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin,201 1,61:212-236.
  • 2Pliarchopoulou K, Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol,2011,79:17-23.
  • 3Ozols RF, Bundy BN, Greer BE, et al. Phase BI trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ili ovarian cancer: a Gynecologic Oncology Group study. J Clin 0ncol,2003,21:3194- 3200.
  • 4Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Tber,2008,30:1426-1447.
  • 5Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer, 2012, 106:6-13.
  • 6Gareia AA, Sill MW, Lankes HA, et al. A phase Ⅱ evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol 0ncol,2012,124:569-574.
  • 7Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res, 2008,68:7905-7914.
  • 8Paes MF, Dalto6 RD, Madeira KP, et al. A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Esptrito Santo, Brazil. J Ovarian Res,2011, 4:14.
  • 9Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Onco1,2005 ,1:221-234.
  • 10Lee CS, Kim YJ, Jang ER, et al. Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines. Eur J Pharmacol,2010,632:7-13.

引证文献1

中华妇产科杂志
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部